Skip to content

Eric Grouzmann

8 papers in the library · 999 citations · publishing 2011-2015

Papers

Sort Most recent Most cited

Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects.

Journal of Pharmacology and Experimental Therapeutics April 2015 Yasmin Schmid, Anna Rickli, Antonia Schaffner et al.

3,4-Methylenedioxymethamphetamine (MDMA; "ecstasy") is a popular recreational drug. The aim of the present study was to explore the role of dopamine in the psychotropic effects of MDMA using bupropion to inhibit the dopamine and norepinephrine transporters through which MDMA releases dopamine and norepinephrine by investigating. The pharmacodynamic and pharmacokinetic interactions between...

Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects

Biological Psychiatry November 29, 2014 Yasmin Schmid, Florian Enzler, Peter Gasser et al. 425 citations

BackgroundAfter no research in humans for >40 years, there is renewed interest in using lysergic acid diethylamide (LSD) in clinical psychiatric research and practice. There are no modern studies on the subjective and autonomic effects of LSD, and its endocrine effects are unknown. In animals, LSD disrupts prepulse inhibition (PPI) of the acoustic startle response, and patients with...

Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination

The International Journal of Neuropsychopharmacology October 8, 2013 Cédric M. Hysek, Linda D. Simmler, Nathalie Schillinger et al. 125 citations

Methylphenidate and 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') are widely misused psychoactive drugs. Methylphenidate increases brain dopamine and norepinephrine levels by blocking the presynaptic reuptake transporters. MDMA releases serotonin, dopamine and norepinephrine through the same transporters. Pharmacodynamic interactions of methylphenidate and MDMA are likely. This study...

α1-Adrenergic Receptors Contribute to the Acute Effects of 3,4-Methylenedioxymethamphetamine in Humans

Journal of Clinical Psychopharmacology July 13, 2013 Cédric M. Hysek, Anja E. Fink, Linda D. Simmler et al. 57 citations

Preclinical studies implicate a role for α₁-noradrenergic receptors in the effects of psychostimulants, including 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). The present study evaluated the effects of the α₁-noradrenergic receptor antagonist doxazosin on the acute pharmacodynamic and pharmacokinetic response to MDMA in 16 healthy subjects. Doxazosin (8 mg/d) or placebo was administered...

Duloxetine Inhibits Effects of MDMA (“Ecstasy") In Vitro and in Humans in a Randomized Placebo-Controlled Laboratory Study

PLoS One May 4, 2012 Cédric M. Hysek, Linda D. Simmler, V.g. Nicola et al. 158 citations

UNLABELLED: This study assessed the effects of the serotonin (5-HT) and norepinephrine (NE) transporter inhibitor duloxetine on the effects of 3,4-methylenedioxy-methamphetamine (MDMA, ecstasy) in vitro and in 16 healthy subjects. The clinical study used a double-blind, randomized, placebo-controlled, four-session, crossover design. In vitro, duloxetine blocked the release of both 5-HT and NE...

Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans

British Journal of Pharmacology March 8, 2012 Cédric M. Hysek, Yasmin Schmid, Anna Rickli et al. 81 citations

BACKGROUND AND PURPOSE The use of ±3,4‐methylenedioxymethamphetamine (MDMA, ‘ecstasy’) is associated with cardiovascular complications and hyperthermia. EXPERIMENTAL APPROACH We assessed the effects of the α 1 ‐ and β‐adrenoceptor antagonist carvedilol on the cardiostimulant, thermogenic and subjective responses to MDMA in 16 healthy subjects. Carvedilol (50 mg) or placebo was administered 1 h...

Effects of the α₂-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers.

Journal of Pharmacology and Experimental Therapeutics February 2012 Cédric M. Hysek, Robin Brugger, Linda D. Simmler et al.

The mechanism of action of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) involves the carrier-mediated and potentially vesicular release of monoamines. We assessed the effects of the sympatholytic α₂-adrenergic receptor agonist clonidine (150 μg p.o.), which inhibits the neuronal vesicular release of norepinephrine, on the cardiovascular and psychotropic response to MDMA (125 mg p.o.) in 16...

The Norepinephrine Transporter Inhibitor Reboxetine Reduces Stimulant Effects of MDMA (“Ecstasy”) in Humans

Clinical Pharmacology & Therapeutics June 15, 2011 Cédric M. Hysek, Linda D. Simmler, M. Ineichen et al. 153 citations

This study assessed the pharmacodynamic and pharmacokinetic effects of the interaction between the selective norepinephrine (NE) transporter inhibitor reboxetine and 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") in 16 healthy subjects. The study used a double-blind, placebo-controlled crossover design. Reboxetine reduced the effects of MDMA including elevations in plasma levels of NE,...